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The N-end rule relates the in vivo half-life of a protein
to the identity of its N-terminal residue. Ubr1p, the rec-
ognition (E3) component of the Saccharomyces cerevi-
siae N-end rule pathway, contains at least two substrate-
binding sites. The type 1 site is specific for N-terminal
basic residues Arg, Lys, and His. The type 2 site is spe-
cific for N-terminal bulky hydrophobic residues Phe,
Leu, Trp, Tyr, and Ile. Previous work has shown that
dipeptides bearing either type 1 or type 2 N-terminal
residues act as weak but specific inhibitors of the N-end
rule pathway. We took advantage of the two-site archi-
tecture of Ubr1p to explore the feasibility of bivalent
N-end rule inhibitors, whose expected higher efficacy
would result from higher affinity of the cooperative (bi-
valent) binding to Ubr1p. The inhibitor comprised
mixed tetramers of b-galactosidase that bore both N-
terminal Arg (type 1 residue) and N-terminal Leu (type 2
residue) but that were resistant to proteolysis in vivo.
Expression of these constructs in S. cerevisiae inhibited
the N-end rule pathway much more strongly than the
expression of otherwise identical b-galactosidase tet-
ramers whose N-terminal residues were exclusively Arg
or exclusively Leu. In addition to demonstrating spatial
proximity between the type 1 and type 2 substrate-bind-
ing sites of Ubr1p, these results provide a route to high
affinity inhibitors of the N-end rule pathway.
Among the targets of the N-end rule pathway are intracel-
lular proteins bearing destabilizing N-terminal residues (1, 2).
This proteolytic pathway is one of several pathways of the
ubiquitin (Ub)1 system, whose diverse functions include the
regulation of cell growth, division, differentiation, and re-
sponses to stress (3–6). Ub is a 76-residue eukaryotic protein
that exists in cells either free or conjugated to other proteins.
Many of the Ub-dependent regulatory circuits involve proces-
sive degradation of ubiquitylated proteins by the 26 S protea-
some, an ATP-dependent multisubunit protease (7, 8).
The N-end rule is organized hierarchically. In the yeast
Saccharomyces cerevisiae, Asn and Gln are tertiary destabiliz-
ing N-terminal residues in that they function through their
conversion, by the NTA1-encoded N-terminal amidase, into the
secondary destabilizing N-terminal residues Asp and Glu. The
destabilizing activity of N-terminal Asp and Glu requires their
conjugation by the ATE1-encoded Arg-tRNA-protein transfer-
ase (R-transferase) to Arg, one of the primary destabilizing
residues (reviewed in Refs. 1 and 9). In mammals, two distinct
N-terminal amidases specific, respectively, for N-terminal Asn
or Gln mediate the conversion of these tertiary destabilizing
residues into the secondary destabilizing residues Asp or Glu
(10, 11). The set of secondary destabilizing residues in verte-
brates contains not only Asp and Glu but also Cys, which is a
stabilizing residue in yeast (9, 12, 13).
The primary destabilizing N-terminal residues are bound
directly by N-recognin, the E3 (recognition) component of the
N-end rule pathway. In S. cerevisiae, N-recognin is the UBR1-
encoded 225-kDa protein that binds to potential N-end rule
substrates through their primary destabilizing N-terminal res-
idues: Phe, Leu, Trp, Tyr, Ile, Arg, Lys, and His (1, 14). The
Ubr1 genes encoding mouse and human N-recognin (also called
E3a) have been cloned as well (15). N-recognin has at least two
substrate-binding sites. The type 1 site is specific for the basic
N-terminal residues Arg, Lys, and His. The type 2 site is
specific for the bulky hydrophobic N-terminal residues Phe,
Leu, Trp, Tyr, and Ile (1, 12, 16, 17). N-recognin can also target
short-lived proteins such as Cup9p (18) and Gpa1p (19, 20),
which lack destabilizing N-terminal residues. The Ubr1p-rec-
ognized degradation signals of these proteins remain to be
characterized in detail.
The known functions of the N-end rule pathway include the
control of di- and tripeptide import in S. cerevisiae through the
degradation of Cup9p, a transcriptional repressor of the pep-
tide transporter gene PTR2 (18, 21); a mechanistically unde-
fined role in the Sln1p-dependent phosphorylation cascade that
mediates osmoregulation in S. cerevisiae (22); the degradation
of Gpa1p, a Ga protein of S. cerevisiae (19, 20); and the condi-
tional degradation of alphaviral RNA polymerase in virus-
infected metazoan cells (23). Physiological N-end rule sub-
strates were also identified among the proteins secreted into
the cytosol of the host cell by intracellular parasites such as the
bacterium Listeria monocytogenes (24). Short half-lives of these
proteins are required for the efficient presentation of their
peptides to the immune system (24). A partial inhibition of the
N-end rule pathway was reported to interfere with mammalian
cell differentiation (25) and to delay limb regeneration in am-
phibians (26). Recent evidence suggests that the N-end rule
pathway mediates a large fraction of the muscle protein turn-
over (27) and plays a role in catabolic states that result in
muscle atrophy (28).
Targeted mutagenesis has been used to inactivate the N-end
rule pathway in Escherichia coli and S. cerevisiae (14, 29).
Analogous mutants have recently been constructed in the
mouse as well.2 These approaches notwithstanding, an effica-
cious inhibitor of the N-end rule pathway would be useful as
well, especially with organisms less tractable genetically. The
emerging understanding of the N-end rule pathway in mam-
mals suggests that selective inhibition or activation of this
proteolytic system may also have medical applications. Previ-
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ous work has shown that millimolar concentrations of amino
acid derivatives such as dipeptides bearing destabilizing N-
terminal residues can selectively inhibit the N-end rule path-
way in extracts from rabbit reticulocytes (12, 17) and Xenopus
eggs (13), and in intact S. cerevisiae cells as well (16). However,
the same dipeptides were observed to have at most marginal
effects on the N-end rule pathway in intact mammalian cells.3
One limitation of dipeptide inhibitors is their apparently low
affinity for the type 1 and the type 2 site of N-recognin (30).
In the present work, we explored the possibility that a biva-
lent ligand can bind simultaneously to the type 1 and type 2
sites of N-recognin (see Fig. 1A). Similarly to the previously
characterized bivalent interactions that involve either macro-
molecules or small molecules (31, 32), the cooperativity of bind-
ing at two independent, mutually nonexclusive sites would be
expected to increase the affinity between N-recognin and a
bivalent inhibitor by orders of magnitude, in comparison with
the affinity of a monovalent binding by the same compound. We
show that a bivalent inhibitor of the N-end rule pathway is
feasible and consider the implications of this advance.
EXPERIMENTAL PROCEDURES
Strains and General Techniques—The S. cerevisiae strains used were
JD52 (MATa ura3-52 his3-D200 leu2-3,112 trp1-D63 lys2-801) and
JD55 (MATa ura3-52 his3-D200 leu2-3,112 trp1-D63 lys2-801 ubr1
D::HIS3) (19, 33). Cells were grown on rich (YPD) or synthetic medium
containing either 2% dextrose (SD medium), 2% galactose (SG medi-
um), or 2% raffinose (SR medium) (34). To induce the PCUP1 promoter,
CuSO4 was added to a final concentration of 0.1 mM. Transformation of
S. cerevisiae was carried out using the lithium acetate method (35).
Plasmids—The high copy (2m-based) plasmids pRD-bgal-TRP1 and
pRD-bgal-HIS3, which expressed Arg-eDK-bgal (Ub-Arg-eDK-bgal) (see
Fig. 2A) from the galactose-inducible PCYC1/GAL1 hybrid promoter (2),
were produced by replacing the URA3 marker gene of pFL7 with either
TRP1 or HIS3. pLD-bgal-TRP1 and pLD-bgal-HIS3, both of which ex-
pressed Leu-eDK-bgal (Ub-Leu-eDK-bgal), were produced by replacing
the Ub-Arg domain of pRD-bgal-TRP1 and pRD-bgal-HIS3 with Ub-Leu
domain of the pLL2 plasmid.4 The plasmid pFL7 was produced from
pUB23-R (2) by converting the lysine codons 15 and 17 of the extension
eK into arginine codons (36, 37), yielding a construct encoding the
extension eDK in front of a bgal moiety lacking the first 23 residues of
wild type bgal (see Fig. 2A). The low copy, pRS315 vector-derived (38)
plasmid pR-eDKhaUra3-R3R7 expressed Arg-eDK-ha-Ura3pK3R,K7R (Ub-
Arg-eDK-ha-Ura3pK3R,K7R) from the PCUP1 promoter. Arg-e
DK-ha-
Ura3pK3R,K7R (see Fig. 2B) is called Arg-Ura3p in the main text. In this
N-end rule substrate, the residues Lys-3 and Lys-7 of the S. cerevisiae
Ura3p were converted to arginines (see “Results and Discussion”). In
addition, the ha epitope tag (39) was placed between eDK and
Ura3pK3R,K7R (see Fig. 2B). The plasmid pR-eDKhaUra3-R3R7 was
produced from pFL1 (encoding Ub-Arg-eDK-ha-Ura3p) through site-di-
rected mutagenesis of the URA3 codons for Lys-3 and Lys-7. pFL1 was
produced from pKM1235 (which encoded Ub-Arg-eK-ha-Ura3p)5 by con-
verting the eK-coding sequence into the one encoding eDK.
Pulse-Chase and Plating Efficiency Assays—Pulse-chase assays with
S. cerevisiae in mid-exponential growth (A600 of ;1) utilized
35S-EX-
PRESS (NEN Life Science Products) and were carried out as described
previously (10, 19), including the immunoprecipitation with anti-bgal
and anti-ha antibodies and quantitation with a PhosphorImager (Mo-
lecular Dynamics, Sunnyvale, CA). To determine plating efficiency, S.
cerevisiae strains JD52 (UBR1) and JD55 (ubr1D) expressing Arg-
Ura3p (Ub-Arg-eDK-ha-Ura3pK3R,K7R; see Fig. 2B) were co-transformed
with plasmids indicated in the legend to Fig. 3. The transformants were
cultured in the raffinose-based medium (SR) lacking Leu, His, and Trp
for 20 h. The cultures were then diluted into the otherwise identical
galactose-containing (SG) medium to a final A600 of 0.1. At an A600 of
0.4, cultures were either supplemented with 0.1 mM CuSO4 or left
unsupplemented. At the A600 of 1.0, the cultures were diluted with SG
(which lacks Leu, His, and Trp) either containing or lacking 0.1 mM
CuSO4 and were plated on the plates of the same medium composition
that also either contained or lacked uracil. The plating efficiency (%)
was defined as the ratio of the number of colonies on SG (2Leu, 2His,
2Trp, 2Ura) plates to the number of colonies on SG (2Leu, 2His,
2Trp) plates, at the same concentration of CuSO4. For each measure-
ment, colonies on 15 plates were counted to yield the average number of
colonies per plate.
RESULTS AND DISCUSSION
We constructed a bivalent N-end rule inhibitor (Fig. 1A) from
the previously studied N-end rule substrates derived from E.
coli bgal (2). In eukaryotes, linear Ub-protein fusions are rap-
idly cleaved by deubiquitylating enzymes at the Ub-protein
junction, making possible the production of otherwise identical
proteins bearing different N-terminal residues, a technical ad-
vance that led to the finding of the N-end rule (2). A bgal-based
N-end rule substrate contains a destabilizing N-terminal resi-
due (produced in vivo using the Ub fusion technique (1)); a
;45-residue, E. coli Lac repressor-derived N-terminal exten-
sion called eK (extension e bearing lysines K); and the bgal
moiety lacking its first 21 residues. The resulting X-eK-bgal is
a short-lived protein in both yeast and mammalian cells,
whereas an otherwise identical protein bearing a stabilizing
N-terminal residue such as Met or Val is metabolically stable
(1, 2). An N-degron comprises a destabilizing N-terminal resi-
due and a Lys residue (or residues), the latter being the site of
formation of a multi-Ub chain (1, 36). (Ubr1p can also recognize
a set of other, internal degrons, which remain to be character-
ized (18).) If Lys-15 and Lys-17 of the eK extension are replaced
by the Arg residues (which cannot be ubiquitylated), the result-
ing X-eDK-bgal (Fig. 2A) is long-lived in vivo even if its N-
terminal residue is destabilizing in the N-end rule (1, 37).
In the present work, we used the metabolically stable Arg-
3 F. Le´vy and A. Varshavsky, unpublished data.
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FIG. 1. The concept of a bivalent inhibitor of the N-end rule
pathway. A, the type 1 and type 2 sites of S. cerevisiae Ubr1p (N-
recognin), which are specific, respectively, for the basic (Arg, Lys, and
His) and bulky hydrophobic (Phe, Leu, Trp, Tyr, and Ile) N-terminal
residues. In the diagram, the type 1 and type 2 sites are occupied by
their ligands, the N-terminal Arg and Leu, borne by a heterodimeric
bivalent inhibitor (actually, a tetrameric bgal-based protein in the
present work). A test substrate bearing Arg, a type 1 destabilizing
N-terminal residue is shown as well. The test substrate, in contrast to
the protein-based inhibitor, bears at least one internal Lys residue (not
indicated in the diagram) that can function as a component of the
N-degron. The type 1 and type 2 sites of N-recognin are shown located
close together in the N-terminal region of the 225-kDa Ubr1p. The
recent genetic dissection of the Ubr1p substrate-binding sites6 placed
the type 1 and type 2 sites close together in the ;60-kDa N-terminal
region of the 225-kDa Ubr1p. B, a diagram illustrating the expected
frequencies of heterodimeric (Arg- and Leu-bearing) dimers within a
bgal-based bivalent inhibitor. Specifically, at equal levels of expression
of the two bgal-based polypeptide chains, 50% of bgal tetramers would
be expected to be heterotetramers in which at least one of the two
dimers bears different (Arg and Leu) N-terminal residues. In the bgal
tetramer, the two N termini of each dimer are spatially close, exposed,
and oriented in the same direction (40). See also “Results and
Discussion.”
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eDK-bgal (produced from Ub-Arg-eDK-bgal) and Leu-eDK-bgal
(produced from Ub-Leu-eDK-bgal). These proteins retain the
ability to bind, respectively, to the type 1 and type 2 sites of
N-recognin but cannot be ubiquitylated (37), apparently be-
cause the most N-terminal Lys residue in X-eDK-bgal, at posi-
tion 239, is too far from the N terminus of the protein. In the
bgal tetramer, the two N termini of each dimer are spatially
close, exposed, and oriented in the same direction (40). At equal
levels of expression of the two bgal-based polypeptide chains
such as Arg-eDK-bgal and Leu-eDK-bgal, 50% of bgal tetramers
would be expected to be heterotetramers in which at least one
of the two dimers bears different (Arg and Leu) N-terminal
residues (Fig. 1B). If the type 1 and type 2 substrate-binding
sites of the 225-kDa Ubr1p are appropriately located and ori-
ented, they might be able to bind the Arg- and Leu-bearing
subunits of the mixed bgal tetramer, especially in view of the
presumed flexibility of the eDK extension (1) (Fig. 1A).
The reporter N-end rule substrate in this study was Arg-eDK-
ha-Ura3pK3R,K7R, denoted below as Arg-Ura3p (Fig. 2B). This
ha-tagged, type 1 N-end rule substrate was produced from
Ub-Arg-eDK-ha-Ura3pK3R,K7R through the cotranslational in
vivo cleavage by deubiquitinating enzymes (1, 6, 41). The ly-
sine-lacking eDK extension of Arg-eDK-ha-Ura3pK3R,K7R, and
the replacement of the first two lysines of the Ura3p moiety
with arginines were used to decrease the rate of degradation of
Arg-Ura3p by the N-end rule pathway and also to reduce the
slow but detectable degradation of Arg-Ura3p by yet another
pathway, through a degron distinct from the N-degron.3 Sev-
eral Lys residues of Ura3p other than Lys-3 and Lys-7 are also
close to its N terminus, thus accounting for the absence, in this
case, of the all-or-none effect on the reporter degradation that
is observed when eK is replaced with eDK in an X-eK-bgal
substrate (37). The Lys-33 Arg and Lys-73 Arg modifications
decreased the enzymatic activity of the Ura3p moiety.2 The
reduced enzymatic activity of Ura3pK3R,K7R facilitated selec-
tion assays (Figs. 3 and 4).
The first bivalent inhibitor assay employed ura3 S. cerevisiae
expressing Arg-Ura3p (Fig. 2B) from the uninduced PCUP1 pro-
moter. The Ubr1p-mediated degradation of Arg-Ura3p (t1⁄2 of
;8 min) and its correspondingly low steady-state concentration
rendered wild type (UBR1) cells phenotypically Ura2, whereas
ubr1D strains expressing Arg-Ura3p were phenotypically Ura1
(Figs. 3 and 4 and data not shown). Cells expressing Arg-Ura3p
were cotransformed with two control plasmids (vectors;
4231424 in Fig. 3). Alternatively, these cells were cotrans-
formed with two plasmids (bearing different selectable mark-
ers) that expressed either Arg-eDK-bgal alone (R1R in Fig. 3),
Leu-eDK-bgal alone (L1L in Fig. 3), or both of them together
(R1L in Fig. 3; the bivalent inhibitor mode) from a galactose-
inducible promoter. Pairs of alternatively marked plasmids
were used to make certain that the conditions of expression and
the total amounts of bgal-based proteins produced remained
the same in all of these settings. The transformants were
streaked on SG medium lacking uracil.
Remarkably, only those Arg-Ura3p-expressing cells that ex-
pressed both Arg-eDK-bgal and Leu-eDK-bgal became Ura1 un-
der these conditions (Fig. 3). The cells that expressed either
Arg-eDK-bgal alone or Leu-eDK-bgal alone remained Ura2, as
did the cells that received control plasmids (Fig. 3). (The same
cells grew equally well in the control SG medium containing
uracil (Fig. 3, bottom left panel).) Note that the monovalent
inhibitors were ineffective despite the fact that the concentra-
tion of either the Arg-based N terminus alone or the Leu-based
N terminus alone was twice the concentration of the same N
termini in the case of the bivalent inhibitor.
To quantify the effect of coexpressing Arg-eDK-bgal and Leu-
eDK-bgal on the rescue of the Ura1 phenotype, a plating effi-
ciency assay was carried out with the same transformants.
Equal amounts of cells were plated on SG(1Ura) and
SG(2Ura) plates, and the numbers of colonies were deter-
mined. When the Arg-Ura3p reporter was expressed at a suf-
ficiently low rate (uninduced PCUP1 promoter), cells became
FIG. 2. Designs of bivalent inhibitor and test substrate. A, the
bgal-based fusions (the residue X was either Arg or Leu) used to
construct the Arg/Leu-bearing bivalent inhibitor. The Ub moiety of the
fusions was cotranslationally removed in vivo by deubiquitinating en-
zymes (1). The ;45-residue, E. coli Lac repressor-derived sequence
termed eDK (extension (e) lacking lysines (DK)), is described in the main
text. The bgal part of the fusion lacked the first 21 residues of wild type
bgal (2). B, the Ura3p-based N-end rule substrate, Arg-eDK-ha-
Ura3pK3R,K7R, derived from Ub-Arg-eDK-ha-Ura3pK3R,K7R and denoted
Arg-Ura3p, is described in the main text.
FIG. 3. A bivalent, but not monovalent, inhibitor of Ubr1p con-
fers Ura1 phenotype on cells expressing the short-lived N-end
rule substrate Arg-Ura3p. S. cerevisiae JD52 (UBR1) expressing
Arg-Ura3p (Ub-Arg-Ura3p), a short-lived reporter (Fig. 2B), were co-
transformed, alternatively, with pRS423 (HIS3-based control vector)
and pRS424 (PGAL1, TRP1-based control vector) (denoted as 4231424);
with pRS424 and pRD-bgal-HIS3, expressing Arg-eDK-bgal (Ub-Arg-
eDK-bgal) (denoted as R1424; monovalent inhibitor); with pRS423 and
pLD-bgal-TRP1, expressing Leu-eDK-bgal (Ub-Leu-eDK-bgal) (denoted
as 4231L); with pRD-bgal-HIS3 and pRD-bgal-TRP1, both expressing
Arg-eDK-bgal (denoted as R1R; monovalent inhibitor); with pLD-bgal-
HIS3 and pLD-bgal-TRP1, both expressing Leu-eDK-bgal (denoted as
L1L); or with pRD-bgal-HIS3 and pLD-bgal-TRP1, expressing Arg-eDK-
bgal and Leu-eDK-bgal (denoted as R1L; the bivalent inhibitor). Cells
were streaked on SG medium containing 0.1 mM CuSO4 and lacking
Leu, His, Trp, and Ura (upper left panel), on the otherwise identical
medium lacking the added CuSO4 (upper right panel), or on the Ura-
containing SG medium lacking Leu, His, and Trp (controls; lower left
panel). Plates were incubated at 30 °C for 3 days.
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Ura1 (through metabolic stabilization of Arg-Ura3p) only in
the presence of both Arg-eDK-bgal and Leu-eDK-bgal (Fig. 4B). A
weak stabilizing effect of Arg-eDK-bgal alone could be detected
only at a ;20-fold higher level of Arg-Ura3p expression (in-
duced PCUP1 promoter) (Fig. 4A). No stabilization of Arg-Ura3p
was observed in the presence of Leu-eDK-bgal under any con-
ditions (Fig. 4), confirming the specificity of inhibition in regard
to the type (basic or bulky hydrophobic) of the primary desta-
bilizing N-terminal residue of the reporter. Higher sensitivity
of this assay at the higher level of Arg-Ura3p expression results
from a higher steady-state level of the short-lived Arg-Ura3p,
so that even its marginal stabilization suffices to render a small
fraction of cells Ura1 (Fig. 4A; compare with Fig. 4B).
To analyze directly the in vivo degradation of Arg-Ura3p in
the presence of different combinations of X-eDK-bgal proteins,
the transformants of Figs. 3 and 4 were subjected to pulse-
chase analysis, with immunoprecipitation of both Arg-Ura3p
and the (long-lived) X-eDK-bgals (Fig. 5). Quantitation of the
resulting electrophoretic patterns (Fig. 5C) confirmed and ex-
tended the conclusions reached through phenotypic analyses
(Figs. 3 and 4). Specifically, the normally short-lived Arg-
Ura3p (Fig. 5A, lanes 1–3) was strongly (but still incompletely)
stabilized in the presence of both Arg-eDK-bgal and Leu-eDK-
bgal (Fig. 5A, lanes 4–6; compare with lanes 1–3 and 7–9). This
stabilization was manifested especially clearly as an increase
in the relative amount of Arg-Ura3p at the beginning of chase
(time 0), indicating reduced degradation of Arg-Ura3p during
the pulse (Fig. 5C). This latter degradation pattern, termed
“zero point effect,” is caused by the previously demonstrated
preferential targeting of newly formed (as distinguished from
conformationally mature) protein substrates by the N-end rule
pathway (16, 42). The increased steady-state level of Arg-
Ura3p in the presence of both Arg-eDK-bgal and Leu-eDK-bgal
accounted for the results of phenotypic analyses (Figs. 3 and 4).
The much smaller but detectable stabilization of Arg-Ura3p by
Arg-eDK-bgal alone (Fig. 5C) was consistent not only with the
inability of Arg-eDK-bgal to confer the Ura1 phenotype on cells
expressing Arg-Ura3p from uninduced PCUP1 promoter but also
with the partial rescue of the Ura1 phenotype by Arg-eDK-bgal
in cells expressing Arg-Ura3p from the induced PCUP1 (Figs. 3
and 4 and data not shown).
FIG. 4. Plating efficiencies of S. cerevisiae expressing Arg-
Ura3p in the presence of bivalent and monovalent inhibitors of
the N-end rule pathway. A, S. cerevisiae JD52 (UBR1) and JD55
(ubr1D) expressing Arg-Ura3p were cotransformed with the sets of
plasmids described and denoted in the legend to Fig. 3. The transfor-
mants were cultured as described under “Experimental Procedures”
and plated on either SG(2Leu, 2His, 2Trp, 2Ura) plates or control
plates SG(2Leu, 2His, 2Trp) containing 0.1 mM CuSO4. The plating
efficiencies shown are the values produced by normalization against the
absolute plating efficiency (92%) of the positive control: the ubr1D
strain JD55 expressing Arg-Ura3p and bearing the vector pRS424. B,
the same experiment was done using plates lacking the added CuSO4.
The plating efficiencies shown are the values produced by normaliza-
tion against the positive control used in A. Under these growth condi-
tions (no added CuSO4), the absolute plating efficiency of the positive
control was 26%.
FIG. 5. Metabolic stabilization of Arg-Ura3p in the presence of
bivalent N-end rule inhibitor. A, S. cerevisiae JD52 (UBR1) express-
ing Arg-Ura3p, a short-lived Ura3p-based reporter (Fig. 2B), from the
induced PCUP1 promoter, were cotransformed, alternatively, with either
pRS423 (HIS3-based control vector) and pRS424 (PGAL1, TRP1-based
control vector) (denoted as 4231424), or with pRD-bgal-TRP1 and pLD-
bgal-HIS3, expressing Arg-eDK-bgal and Leu-eDK-bgal (denoted as R1L;
the bivalent inhibitor). Control JD55 (ubr1D) cells expressing Arg-
Ura3p were transformed with pRS424. Cells grown in either dextrose-
containing SD medium (no expression of bgal) or galactose-containing
SG medium were labeled with [35S]methionine/cysteine for 5 min at
30 °C, followed by a chase for 0, 10, and 30 min, extraction, immuno-
precipitation, and SDS-10% polyacrylamide gel electrophoresis. B,
same as in A, but cells were also cotransformed with the plasmids
pRD-bgal-TRP1 and pRD-bgal-HIS3, both expressing Arg-eDK-bgal (de-
noted as R1R). The assays were carried out in SG medium. C, in vivo
decay curves of Arg-Ura3p (Fig. 2B) in wild type (JD52) and ubr1D
(JD55) cells. The patterns in A and B were quantified as described
under “Experimental Procedures.” The initial amounts of Arg-Ura3p
were normalized against the amount in ubr1D cells (100%). Note that
the inhibitors also altered the zero point effect (degradation of a re-
porter during the pulse (16, 42)). l, degradation of Arg-Ura3p in UBR1
(JD52) cells in the presence of both Arg-eDK-bgal and Leu-eDK-bgal (cells
were grown in SG medium); E, the same transformants were grown in
SD medium where bgal fusions were not expressed; , JD52 cells
expressing Arg-Ura3p were transformed with the two alternatively
marked plasmids expressing Arg-eDK-bgal and grown in SG medium; M,
JD52 cells expressing Arg-Ura3p were transformed with the two alter-
natively marked control vectors and grown in SG medium; f, ubr1D
(JD55) cells expressing Arg-Ura3p were transformed with control vec-
tors and grown in SG medium.
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The Arg/Leu-eDK-bgal-based bivalent inhibitor of the present
work, although surprisingly potent (Fig. 4B), is obviously far
from optimal even for a protein-based inhibitor; because bgal is
a homotetramer, only ;50% of the coexpressed Arg-eDK-bgal
and Leu-eDK-bgal chains would exist as heterodimers within
tetramers (Fig. 1B). (This estimate assumes a random assort-
ment of Arg- and Leu-bearing bgal chains in the formation of
bgal tetramers. The actual in vivo assortment is expected to be
biased, to an unknown extent, in favor of homodimeric associ-
ations, because individual polysomes would produce bgal
chains bearing either Arg or Leu but not both.) In addition,
although the eDK extension (Fig. 2A) is capable of supporting
the desired effects, it is also unlikely to be optimal. In sum-
mary, the efficacy of this first and necessarily suboptimal bi-
valent inhibitor bodes well for the future of this design.
A bivalent inhibitor is strikingly more efficacious than an
otherwise identical monovalent inhibitor (Figs. 3–5). In addi-
tion, our findings are the first evidence that the type 1 and type
2 sites of N-recognin are spatially proximal in the 225-kDa S.
cerevisiae Ubr1p. While this work was under way, genetic
dissection of S. cerevisiae Ubr1p identified amino acid residues
that are required for the integrity of the type 1 site but not the
type 2 site, and vice versa.6 These results provided independent
evidence for both the separateness and spatial proximity of the
two substrate-binding sites of the 225-kDa N-recognin, in
agreement with the present data. Our results (Figs. 3–5)
strongly suggest that small bivalent inhibitors of the N-end
rule pathway are feasible, and moreover, are expected to be
much more potent than their monovalent counterparts. Work
to produce such inhibitors is under way.
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